New hope for tough cancers: testing Triple-Threat drug combos
NCT ID NCT07397338
Summary
This study is testing new combinations of experimental drugs for people with advanced solid tumors that have specific RAS mutations. Researchers want to see if combining a new type of drug called a RAS(ON) inhibitor with another cancer drug called ivonescimab is safe and can help control cancer growth. The trial will involve about 370 adults whose cancers have progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eastern Connecticut Hematology and Oncology Associates
RECRUITINGNorwich, Connecticut, 06360, United States
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37023, United States
Conditions
Explore the condition pages connected to this study.